Opens in a new tab

Dr. Ma Jun

Chinese name: 马骏
Academician of the Chinese Academy of Sciences, Chief Physician, Professor, Doctoral Supervisor, Chief Expert in Nasopharyngeal Carcinoma . Radiation Oncology
Dr. Ma Jun is Executive Deputy Director of Sun Yat-sen University Cancer Center and an academician of the Chinese Academy of Sciences. A world-leading expert in nasopharyngeal carcinoma, he focuses on improving survival and quality of life through optimized radiotherapy and chemo-radiotherapy strategies that have changed international treatment guidelines.

Private & confidential

No obligation

Coordinated end-to-end by Orisene

30+ years
Clinical experience
100+ SCI papers
Academic output
3 national prizes
National awards

  • The Physician

About Dr. Ma Jun

Dr. Ma Jun is Executive Deputy Director of Sun Yat-sen University Cancer Center and an academician of the Chinese Academy of Sciences. Over a career spanning 40 years he has led original research on nasopharyngeal carcinoma, improving survival and quality of life for patients worldwide. As corresponding author he has published over 190 papers, including in the New England Journal of Medicine, Lancet, JAMA and BMJ, with more than 10,000 total citations. He has won three National Science and Technology Progress Second Prizes as first completer, and several AJCC/UICC staging and US treatment-pathway revisions are based on his work. He is President-elect of the International Gordon Conference on Nasopharyngeal Carcinoma.
1、Executive Deputy Director of Sun Yat-sen University Cancer Center and Director of the Guangdong Nasopharyngeal Carcinoma Clinical Research Center
2、Academician of the Chinese Academy of Sciences; professor, chief physician and doctoral supervisor with 40 years of clinical and research experience
3、Published over 190 papers as corresponding author with more than 10,000 total citations, including 19 ESI highly cited papers and 3 hot papers
4、Won three National Science and Technology Progress Second Prizes as first completer, plus the Ho Leung Ho Lee Award and the Tan Jiazhen Clinical Medicine Award
5、Chairman of the CSCO and CACA Nasopharyngeal Carcinoma Committees and President-elect of the International Gordon Conference on Nasopharyngeal Carcinoma
6、Core member of the AJCC nasopharyngeal carcinoma staging committee, with 9 of 15 staging revisions based on his research

Dr. Ma Jun ’s Three Key Areas of Expertise

Three areas of focused expertise, each supported by a deep subspecialty team, high case volumes and an English-speaking care pathway coordinated by Orisene.

Nasopharyngeal carcinoma

Optimized intensity-modulated radiotherapy and chemo-radiotherapy strategies; his randomized trials established induction chemotherapy and reduced-intensity approaches that raise cure rates while lowering toxicity for patients with locally advanced disease and help preserve organ function and quality of life during and after treatment.

Locally advanced nasopharyngeal carcinoma

De-escalation and precision radiotherapy; his randomized trials defined which low-risk patients can safely receive radiotherapy alone, sparing them unnecessary chemotherapy and its side effects and improving quality of life while maintaining excellent tumor control and long-term survival for carefully selected patients.

Head and neck cancers

Multidisciplinary radiotherapy and combined-modality management; his research on distant metastasis prevention and metronomic adjuvant chemotherapy has improved long-term survival and become part of international guidelines for nasopharyngeal carcinoma, guiding combined treatment for patients with head and neck tumors around the world.

More: nasopharyngeal carcinoma screening, recurrence and metastasis management, and radiotherapy for other head and neck tumors

  • Clinical Practice & Publications

Selected cases, research & publications

Representative work drawn from documented clinical treatments, publicly indexed literature, and hospital project records, reflecting the depth of this physician's hands-on expertise and academic rigor.
1. TPF Induction Chemotherapy Plus Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
Landmark phase 3 trial led by Professor Ma Jun showing that adding docetaxel, cisplatin and fluorouracil (TPF) induction chemotherapy before concurrent chemoradiotherapy significantly improved failure-free survival in patients with locoregionally advanced nasopharyngeal carcinoma, compared with chemoradiotherapy alone. This changed global treatment guidelines for nasopharyngeal cancer and helps patients seeking induction chemotherapy for advanced nasopharyngeal carcinoma.
2. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
A multicenter, randomized phase 3 trial from Professor Ma Jun’s team demonstrating that gemcitabine plus cisplatin (GP) induction chemotherapy added to concurrent chemoradiotherapy significantly improved recurrence-free and overall survival in locoregionally advanced nasopharyngeal carcinoma. This regimen became a widely recommended induction option, helping patients searching for gemcitabine cisplatin chemotherapy for nasopharyngeal carcinoma worldwide.
3. Long-Term Survival Outcomes of TPF Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Carcinoma
Long-term follow-up of a phase 3 randomized controlled trial confirmed that docetaxel, cisplatin and fluorouracil (TPF) induction chemotherapy plus concurrent chemoradiotherapy produced durable five-year survival gains in locoregionally advanced nasopharyngeal carcinoma, with no marked increase in late toxicities. Useful evidence for patients considering induction chemotherapy and IMRT for advanced nasopharyngeal carcinoma.
4. Adjuvant Metronomic Capecitabine After Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma
Phase 3 trial showing that one year of adjuvant metronomic capecitabine after standard chemoradiotherapy significantly improved failure-free survival in high-risk locoregionally advanced nasopharyngeal carcinoma, with manageable hand-foot syndrome. Professor Ma Jun’s team established this low-toxicity oral maintenance strategy for patients with nasopharyngeal carcinoma at high risk of recurrence.
5. Intensity-Modulated Radiotherapy Versus Conventional Radiotherapy for Nasopharyngeal Carcinoma
Comparative study showing that intensity-modulated radiotherapy (IMRT) improved target coverage and reduced radiation to nearby organs at risk compared with conventional two-dimensional radiotherapy in nasopharyngeal carcinoma, yielding better tumor control and fewer side effects. This evidence helped establish IMRT as the standard radiation technique, guiding patients seeking IMRT for nasopharyngeal carcinoma.
6. Refining the AJCC/UICC Eighth Edition Staging System for Nasopharyngeal Carcinoma
International study supporting the 8th edition AJCC/UICC staging system for nasopharyngeal carcinoma, refining T and N categories for the IMRT era so doctors can better predict prognosis and select the right treatment intensity, from radiotherapy alone to combined chemoradiotherapy, for each patient’s nasopharyngeal cancer.
  • Affiliated Hospital

Where Dr. Ma Jun practices

Guangzhou

Sun Yat-sen University Cancer Center

Chinese name: 中山大学肿瘤防治中心
Sun Yat-sen University Cancer Center, founded in 1964, is South China's leading oncology institute and the nation's top-ranked cancer center in scientific impact, ranking fifth worldwide on the 2024 Nature Index, with 6 academicians and one of Asia's finest radiotherapy centers.
Since 1964
62 years of cancer care
2,245
Licensed beds
2.56 million
Annual outpatient visits
6
Licensed beds
View Hospital Profile
Appointments with this physician are booked through official hospital channels only, coordinated end-to-end by Orisene.
  • WHY INTERNATIONAL PATIENTS CHOOSE CHINA

Why patients travel to China for treatment

Six reasons international patients now put China on their shortlist — from internationally aligned clinical capability to the policy channels that make treatment here genuinely reachable.

Clinical capability at international standard

Chinese hospitals deliver internationally aligned protocols, performing vast volumes of advanced robotic, minimally invasive, and complex transplant surgeries annually. This massive clinical data and highly specialized workforce ensure world-class outcomes, even for rare and complex cases.

Diagnostics and treatment in days, not months

A full medical workup that typically means months of waiting elsewhere is completed in China within 48–72 hours. Imaging, labs, and multidisciplinary consultations are integrated into a single visit, allowing treatment to commence immediately.

Transparent, itemised pricing

Chinese healthcare offers legally binding, itemised cost estimates before treatment begins, eliminating hidden fees or surprise billing. Due to national centralized procurement, total expenses remain 40–70% lower than comparable care in Western Europe or North America.

Policy channels that open the door

China facilitates access through 240-hour visa-free transit and dedicated medical visa routes. Policies like the Greater Bay Area drug pathway and Boao Lecheng’s pilot zone allow designated hospitals to administer innovative therapies not yet globally approved.
  • International Patient Guide

Consulting this physician, step by step

From the first message to the follow-up after you fly home, one coordinator, no paperwork on your side.
01
Day 0
  • Share your story
    A private consultation with an Orisene advisor, by message, phone or video. Send medical records in any language. Nothing is shared with the hospital yet.
02
Days 1–3
  • Records review & matching
    Orisene translates and presents your case to the right specialist. The hospital returns a tailored care plan, with costs itemised once that plan is confirmed.
03
Days 3–7
  • Your consultation
    Appointments are booked through official hospital channels only. Your navigator accompanies every visit with real-time interpretation, so you can focus on one thing: being cared for.
04
After you fly home
  • Reports & follow-up
    Translated reports and prescriptions delivered within days, remote follow-up coordination with your physicians at home, and a standing line to your navigator.
Orisene offers English and multilingual services, a professional medical interpreter at every consultation, plus translation of your records, reports and prescriptions.

Ready to plan your consultation with Dr. Ma Jun?

Send your records in any language. An Orisene advisor will reply within 2 hours, present your case to the right specialist, and return a tailored care plan with itemised costs, before anything is booked. Simple. Private. Efficient.
Contact

Confidential, permanently

Independent — no hospital commission

We never handle medical fees

Information Sources

This physician profile is compiled by the Orisene team from publicly available online sources and verified at the time of publication. Details may change, and physician availability is confirmed at the time of booking.

Disclaimer: This information is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personal medical guidance.

Mention of any specific product, brand, or manufacturer is for informational purposes only and does not constitute an endorsement or recommendation by Dr. Ma Jun.